Humira Related Published Studies
Well-designed clinical trials related to Humira (Adalimumab)
Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. [2009.11]
Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. [2009.11]
A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. [2009.08]
Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. [2009.07]
Adalimumab for the treatment of fistulas in patients with Crohn's disease. [2009.07]
Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. [2009.07]
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. [2009.06]
Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. [2009.05]
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). [2009.05]
Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. [2009.04]
Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. [2009.04]
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. [2009]
Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. [2008.12.09]
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. [2008.12]
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. [2008.11]
Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. [2008.10.15]
Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. [2008.10.15]
Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. [2008.10.02]
Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. [2008.10]
Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. [2008.09]
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. [2008.08.21]
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. [2008.07]
Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). [2008.07]
Adalimumab Reduces Pain, Fatigue, and Stiffness in Patients with Ankylosing Spondylitis: Results from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for Ankylosing Spondylitis (ATLAS). [2008.05.15]
Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. [2008.03]
Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. [2008.02]
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. [2008.01]
Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. [2008]
Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. [2007.11.28]
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. [2007.11]
Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. [2007.11]
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. [2007.10.11]
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. [2007.09]
Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. [2007.08.15]
Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study. [2007.07.30]
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. [2007.06.19]
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. A Randomized Trial. [2007.04.30]
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. [2007.02]
Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. [2007]
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. [2006.10]
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. [2006.07]
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. [2006.06]
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. [2006.02]
Safety Analyses of Adalimumab (HUMIRA(R)) in Global Clinical Trials and US Postmarketing Surveillance of Patients With Rheumatoid Arthritis. [2006.01.26]
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. [2006.01]
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. [2005.10]
Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. [2005]
Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. [2004.06]
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. [2004.05]
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. [2004.05]
Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. [2004]
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). [2003.12]
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. [2003.12]
Role of adalimumab in the treatment of early rheumatoid arthritis. [2003.09]
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. [2003.06]
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. [2003.01]
A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. [2002.11]
Well-designed clinical trials possibly related to Humira (Adalimumab)
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. [2009.07.18]
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. [2009.07]
Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. [2009.06]
Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. [2009.05]
Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. [2008.06]
Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial. [2008.04.15]
Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. [2008.01]
Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. [2008]
Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. [2007.11]
[Rituximab in patients with rheumatoid arthritis: systematic review.] [2007.10.07]
Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. [2007.06.15]
Validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging spinal inflammation index: is it necessary to score the entire spine? [2007.04.15]
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomized controlled trials and clinical practice. [2007.04.10]
Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer? [2007.03]
[The role of biological agents in the treatment of psoriatic arthritis, literature review] [2006.10.15]
The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. [2006.09.27]
[A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens] [2006.01]
Lefunomide in combination therapy. [2004.06]
Other research related to Humira (Adalimumab)
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. [2009.01.15]
Adalimumab-induced acute myelogenic leukemia. [2008.12]
Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial. [2008.10.03]
Refractory dissecting cellulitis of the scalp treated with adalimumab. [2008.10]
Efficacy of adalimumab in plaque psoriasis: experience on 28 patients. [2008.10]
Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. [2008.10]
Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. [2008.09]
Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. [2008.09]
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. [2008.08.13]
Adalimumab for long-term treatment of psoriatic arthritis: two-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). [2008.08.06]
Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study. [2008.08.03]
Short-term Influence of Adalimumab on Work Productivity Outcomes in Patients with Rheumatoid Arthritis. [2008.08.01]
A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: Effects of adalimumab treatment on synovial tissue. [2008.07.22]
Adalimumab for the treatment of Crohn's disease. [2008.07]
[The use of adalimumab in severe fistulising Crohn's disease] [2008.06.16]
Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. [2008.06.15]
Adalimumab therapy for refractory uveitis: a pilot study. [2008.06]
Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab. [2008.06]
Treating psoriasis with adalimumab. [2008.04]
Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults. [2008.04]
Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. [2008.03.12]
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. [2008.03]
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). [2008.03]
The use of adalimumab in the management of refractory Crohn's disease. [2008.02.15]
Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up. [2008.02]
Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. [2008.02]
|
